Oramed Pharma Cmn (ORMP) 7.74 $ORMP
Oramed to Present at the Aegis Capital Growth Conference
PR Newswire - Mon Sep 19, 8:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place September 20-22, 2016 in Las Vegas. David Slager, Director of Oramed, will present a corporate overview on September 21, 2016.
ORMP: 7.74 (-0.10)
Oramed to Present at the Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Sep 07, 7:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 18th Annual Global Investment Conference, taking place September 11-13, 2016 in New York City. Nadav Kidron, Oramed's CEO, will present a corporate overview on September 12, 2016.
ORMP: 7.74 (-0.10)
Oramed Receives Additional $4 Million Milestone Payment From HTIT
PR Newswire - Tue Aug 02, 8:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received a milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone, part of a previously-announced license and investment agreement between Oramed and HTIT, follows Oramed's report of additional positive efficacy and safety data from its recently completed Phase IIb trial of its oral insulin product, ORMD-0801.
ORMP: 7.74 (-0.10)
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo
PR Newswire - Thu Jul 28, 7:15AM CDT
Statistically Significant Results Across Key Glycemic Endpoints
ORMP: 7.74 (-0.10)
Oramed to Present at the American Diabetes Association 76th Scientific Sessions
PR Newswire - Thu Jun 09, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented in a poster at the ADA 76th Scientific Sessions on June 11-13, 2016 in New Orleans. The poster was also selected to be included in a moderated tour of select posters.
ORMP: 7.74 (-0.10)
Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
PR Newswire - Wed May 18, 6:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin capsule (ORMD-0801) in patients with type 2 diabetes. The study's primary objective, a significant reduction of weighted mean night-time glucose, was successfully achieved.
ORMP: 7.74 (-0.10)
Oramed Patent Being Granted in China for Oral Administration of Proteins
PR Newswire - Wed May 11, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.
ORMP: 7.74 (-0.10)
Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
PR Newswire - Thu Apr 28, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on May 5, 2016 in New York. Nadav Kidron, CEO of Oramed, will present a corporate overview at the conference.
ORMP: 7.74 (-0.10)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.24 (-0.22), JNJ: 117.78 (-1.03), ABT: 41.68 (-0.51), VTVT: 7.23 (+0.06), NVO: 44.43 (-0.45), ORMP: 7.74 (-0.10), AMGN: 173.53 (-1.27), GSK: 42.96 (-0.46)
Oramed to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Feb 04, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18th Annual BIO CEO & Investor Conference, taking place February 8-9, 2016 in New York City. Nadav Kidron, CEO of Oramed, will present a corporate overview on February 8, 2016.
ORMP: 7.74 (-0.10)
Oramed reports 1Q loss
Automated Insights - Wed Jan 13, 3:23PM CST
JERUSALEM (AP) _ Oramed Pharmaceuticals Inc. (ORMP) on Wednesday reported a loss of $2.4 million in its fiscal first quarter.
ORMP: 7.74 (-0.10)
Oramed Pharmaceuticals' Shareholder Letter
PR Newswire - Wed Jan 06, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), today issued the following shareholder letter:
ORMP: 7.74 (-0.10)
Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
PR Newswire - Tue Dec 29, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT"
. Oramed has sold 1,155,367 restricted shares of Common Stock at a price of $10.39 per Share, for an aggregate amount of $12 million. Oramed has additionally received approval from the Office of the Chief Scientist of the Israeli Ministry of Economy ("OCS" for the out-licensing agreement with HTIT. Following receipt of the OCS's approval, the out-licensing deal for ORMD-0801, a novel oral insulin capsule, has now closed. Under the terms of the agreement, Oramed has granted HTIT exclusive rights for commercialization of ORMD-0801 in Greater China. The license includes multiple milestone payments aggregating $38 million and up to a 10% royalty, based on net sales of the product in China.
ORMP: 7.74 (-0.10)
$50 Million Plus Royalties Deal Indicates Blockbuster Future for Oramed's Oral Insulin
ACCESSWIRE - Tue Dec 01, 8:00AM CST
Oramed's deal with China's leading insulin manufacturer and technology incubator Hefei aims to bring novel medicine to the large Chinese diabetes market; Deal includes ongoing 10% royalty in a multi-billion dollar industry
ORMP: 7.74 (-0.10)
Ford and Vale are big market movers
AP - Mon Nov 30, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.31 (-0.23), F: 12.01 (-0.16), CSC: 51.56 (-0.01), ORMP: 7.74 (-0.10), VALE: 5.38 (-0.04), MCUR: 1.47 (+0.02), ODP: 3.60 (-0.11)
Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
PR Newswire - Mon Nov 30, 7:16AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has signed definitive licensing and investment agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT" for exclusive rights to market Oramed's oral insulin capsule, ORMD-0801, in China, Hong Kong and Macau. The agreements were signed at the Israel Knesset (Parliament).
ORMP: 7.74 (-0.10)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 44.43 (-0.45), LXRX: 18.37 (-0.26), ORMP: 7.74 (-0.10), MRK: 62.15 (-0.81), OSIR: 4.69 (-0.09), LLY: 79.52 (-1.64), BMY: 55.48 (-1.00), XOMA: 0.49 (-0.03)
Oramed Patent Allowed in the US for Oral Administration of Proteins
PR Newswire - Thu Sep 24, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been allowed by the United States Patent and Trademark Office.
ORMP: 7.74 (-0.10)
Interest Rate Decision Hasn't Phased Micro Cap Stocks
ACCESSWIRE - Wed Sep 09, 11:21AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 9, 2015 / This has been a looming issue for the better part of the last few months: The Fed's decision on what to do about interest rates in the US. The decision will be made known next week but according to some, the real "drama" that some had expected to see in other markets like the bond or even treasuries may simply be a non-event. Doug Duncan, chief economist for Fannie Mae recently told Yahoo Finance's Mike Santoli, "Expectations for a Fed hike built into futures prices suggest there's still only something like 30% chance assigned to a September move. If the Fed wants market expectations more aligned with its policy intentions before a rate change, then you would make the argument that they'll put it off."
ORMP: 7.74 (-0.10), LLY: 79.52 (-1.64)
Oramed to Present at the Aegis Capital Growth Conference
PR Newswire - Mon Sep 19, 8:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place September 20-22, 2016 in Las Vegas. David Slager, Director of Oramed, will present a corporate overview on September 21, 2016.
ORMP: 7.74 (-0.10)
Oramed to Present at the Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Sep 07, 7:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 18th Annual Global Investment Conference, taking place September 11-13, 2016 in New York City. Nadav Kidron, Oramed's CEO, will present a corporate overview on September 12, 2016.
ORMP: 7.74 (-0.10)
Oramed Receives Additional $4 Million Milestone Payment From HTIT
PR Newswire - Tue Aug 02, 8:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received a milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone, part of a previously-announced license and investment agreement between Oramed and HTIT, follows Oramed's report of additional positive efficacy and safety data from its recently completed Phase IIb trial of its oral insulin product, ORMD-0801.
ORMP: 7.74 (-0.10)
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo
PR Newswire - Thu Jul 28, 7:15AM CDT
Statistically Significant Results Across Key Glycemic Endpoints
ORMP: 7.74 (-0.10)
Oramed to Present at the American Diabetes Association 76th Scientific Sessions
PR Newswire - Thu Jun 09, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented in a poster at the ADA 76th Scientific Sessions on June 11-13, 2016 in New Orleans. The poster was also selected to be included in a moderated tour of select posters.
ORMP: 7.74 (-0.10)
Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
PR Newswire - Wed May 18, 6:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin capsule (ORMD-0801) in patients with type 2 diabetes. The study's primary objective, a significant reduction of weighted mean night-time glucose, was successfully achieved.
ORMP: 7.74 (-0.10)
Oramed Patent Being Granted in China for Oral Administration of Proteins
PR Newswire - Wed May 11, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.
ORMP: 7.74 (-0.10)
Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
PR Newswire - Thu Apr 28, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on May 5, 2016 in New York. Nadav Kidron, CEO of Oramed, will present a corporate overview at the conference.
ORMP: 7.74 (-0.10)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.24 (-0.22), JNJ: 117.78 (-1.03), ABT: 41.68 (-0.51), VTVT: 7.23 (+0.06), NVO: 44.43 (-0.45), ORMP: 7.74 (-0.10), AMGN: 173.53 (-1.27), GSK: 42.96 (-0.46)
Oramed to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Feb 04, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18th Annual BIO CEO & Investor Conference, taking place February 8-9, 2016 in New York City. Nadav Kidron, CEO of Oramed, will present a corporate overview on February 8, 2016.
ORMP: 7.74 (-0.10)
Oramed reports 1Q loss
Automated Insights - Wed Jan 13, 3:23PM CST
JERUSALEM (AP) _ Oramed Pharmaceuticals Inc. (ORMP) on Wednesday reported a loss of $2.4 million in its fiscal first quarter.
ORMP: 7.74 (-0.10)
Oramed Pharmaceuticals' Shareholder Letter
PR Newswire - Wed Jan 06, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), today issued the following shareholder letter:
ORMP: 7.74 (-0.10)
Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
PR Newswire - Tue Dec 29, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT"
. Oramed has sold 1,155,367 restricted shares of Common Stock at a price of $10.39 per Share, for an aggregate amount of $12 million. Oramed has additionally received approval from the Office of the Chief Scientist of the Israeli Ministry of Economy ("OCS" for the out-licensing agreement with HTIT. Following receipt of the OCS's approval, the out-licensing deal for ORMD-0801, a novel oral insulin capsule, has now closed. Under the terms of the agreement, Oramed has granted HTIT exclusive rights for commercialization of ORMD-0801 in Greater China. The license includes multiple milestone payments aggregating $38 million and up to a 10% royalty, based on net sales of the product in China. ORMP: 7.74 (-0.10)
$50 Million Plus Royalties Deal Indicates Blockbuster Future for Oramed's Oral Insulin
ACCESSWIRE - Tue Dec 01, 8:00AM CST
Oramed's deal with China's leading insulin manufacturer and technology incubator Hefei aims to bring novel medicine to the large Chinese diabetes market; Deal includes ongoing 10% royalty in a multi-billion dollar industry
ORMP: 7.74 (-0.10)
Ford and Vale are big market movers
AP - Mon Nov 30, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.31 (-0.23), F: 12.01 (-0.16), CSC: 51.56 (-0.01), ORMP: 7.74 (-0.10), VALE: 5.38 (-0.04), MCUR: 1.47 (+0.02), ODP: 3.60 (-0.11)
Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
PR Newswire - Mon Nov 30, 7:16AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has signed definitive licensing and investment agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"
for exclusive rights to market Oramed's oral insulin capsule, ORMD-0801, in China, Hong Kong and Macau. The agreements were signed at the Israel Knesset (Parliament). ORMP: 7.74 (-0.10)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 44.43 (-0.45), LXRX: 18.37 (-0.26), ORMP: 7.74 (-0.10), MRK: 62.15 (-0.81), OSIR: 4.69 (-0.09), LLY: 79.52 (-1.64), BMY: 55.48 (-1.00), XOMA: 0.49 (-0.03)
Oramed Patent Allowed in the US for Oral Administration of Proteins
PR Newswire - Thu Sep 24, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been allowed by the United States Patent and Trademark Office.
ORMP: 7.74 (-0.10)
Interest Rate Decision Hasn't Phased Micro Cap Stocks
ACCESSWIRE - Wed Sep 09, 11:21AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 9, 2015 / This has been a looming issue for the better part of the last few months: The Fed's decision on what to do about interest rates in the US. The decision will be made known next week but according to some, the real "drama" that some had expected to see in other markets like the bond or even treasuries may simply be a non-event. Doug Duncan, chief economist for Fannie Mae recently told Yahoo Finance's Mike Santoli, "Expectations for a Fed hike built into futures prices suggest there's still only something like 30% chance assigned to a September move. If the Fed wants market expectations more aligned with its policy intentions before a rate change, then you would make the argument that they'll put it off."
ORMP: 7.74 (-0.10), LLY: 79.52 (-1.64)
